Consensus $5.45. Sees FY25 adjusted revenue up 3.4%-3.9%. Raises FY25 organic revenue view to up 4.75%-5% from 4.5%-5%. “We’re restoring our earnings power through our focus on underlying margin improvement, delivering another quarter of high-single digit constant currency adjusted EPS growth,” said Gary Corona, Medtronic (MDT) interim chief financial officer. “And now, as the impact from foreign currency abates, we expect to report high-single digit adjusted EPS growth in the back half of our fiscal year, in line with our long-term commitment to deliver durable, mid-single digit organic revenue growth with EPS leverage.”
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- Medtronic reports Q2 EPS $1.26, consensus $1.25
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, November 18 – November 21, 2024
- Medtronic (MDT) Q2 Earnings Cheat Sheet
- Medtronic sued by Hexagon Health over hernia mesh patents
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
